JPRN-UMIN000018606已完成未知
Phase I study of Ramucirumab and Irinotecan for metastatic gastric cancer previously treated with Fluoropyrimidine with/without Platinum and Taxane. - G-IRIRAMstudy
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) active synchronous or metachronous malignancy 2) previously treated with irinotecan 3) uncontrolled hypertension 4) active infection 5) serious coexisting illness 6) intensive surgery within 28 days prior to the registration 7) embolism and thrombosis, or grade 3 or more GI bleeding within 3 months prior to the registration 8) uncontrolled diarrhea 9) severe allergy 10) moderate or more pleural effusion/ascites 11) systemic steroid user 12) severe mental disorders 13) symptomatic central metastasis 14) atazanavir user 15) pregnant or nursing 16) active hepatitis 17) UGT1A1*6/*6, *28/*28, *6/*28 18) other conditions not suitable for this study
研究者
相似试验
进行中（未招募）
2 期
A phase II trial of ramucirumab plus irinotecan for patients with early relapced gastric cancerGastric cancer, early relapse, irinotecan, ramucirumabD013274Gastric cancerJPRN-jRCTs051190071YAMAGUCHI Toshifumi40
已完成
不适用
Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancerchemo-refractory gastric cancerJPRN-UMIN000019075Osaka University6
已完成
2 期
HGCSG1603gastric cancerJPRN-jRCTs011180029Komatsu Yoshito35
未知
1 期
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaStomach NeoplasmsJPRN-jRCT2080222764Eli Lilly Japan K.K.
进行中（未招募）
1 期
A sing le-arm, phase I study of ramucirumab in combination with erlotinib or osimertinib in previously untreated patients with EGFR mutantion-posit ive metastatic Non-small cell lung cancer with brain metastaseslung carcinoma, non small cellD002289JPRN-jRCT2051190027Kaneda Hiroyasu6